Y. Seo

University of California, San Francisco
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (56)

Figure S4: Gamma energy spectra of the tumor, blood, kidneys, and bone showing the intensities of the 213Bi and 221Fr peaks. As compared to the equilibrium gamma energy spectra of [225Ac]DOTA-YS5, increased intensity of the 213Bi was observed in kidney samples.

Year:

2025

Figure S11: Antitumor activity of [225Ac]DOTA-YS5 in subcutaneous DU145 tumors in nude mice. Tumor volume, survival analysis, and weight measurements after the injections of [225Ac]DOTA-YS5 in DU145 xenografts (n=6).

Year:

2025

Figure S10: Tumor volumes, overall survival, and body weights for the saline and fractionated dose (0.125 µCi x 3) injections in 22Rv1 xenografts. Results show delayed tumor growth and improved survival without the significant toxicity from fractionated dose treatment (n=10).

Year:

2025

Figure S9: Histology evaluation of the healthy tissues for long-term (117 days) toxicity analysis. Hematoxylin and Eosin (H&E) staining of spleen, liver, lungs, heart, and bone samples show no toxicity at 0.25 µCi or 0.5 µCi doses of [225Ac]DOTA-YS5. Scale bar: 20 µm

Year:

2025

Figure S7: Analysis of CD46 expression in correlation with of the [225Ac]DOTA-YS5 uptake and DNA damage. Digital autographs, H &E staining, and immunofluorescence (Rabbit Isotype control+DAPI, CD46 & phospho-γ-H2Ax) of the tumor tissues injected with [225Ac]DOTA-YS5 for day 1, day 2, day 4, and day 7.

Year:

2025

Figure S8: Acute toxicity study of the [225Ac]DOTA-YS5 in nude mice (n=5). A The body weights of mice injected with [225Ac]DOTA-YS5 showed no significant change in treatment groups over the 15 days study period. B&C: Liver and kidney function tests (B) and blood parameters (C) show no significant changes for saline vs. treated groups indicating the short-term safety of [225Ac]DOTA-YS5.

Year:

2025

Figure S2: A, MALDI-TOF Mass spectroscopy results show 8.7 equivalents of DOTA molecules on the YS5 antibody. The number of DOTA were calculated by dividing the difference of m/z between YS5 and DOTA-YS5 by the molecular weight of DOTA. B, Size-exclusion chromatogram shows no aggregation of the [225Ac]DOTA-YS5 after the radiolabeling steps. C, Stability of the [225Ac]DOTA-YS5 tested in saline and human serum for 14 days. D, Comparison of the binding assay results after attaining secular equilibrium vs without secular equilibrium. No significant difference was observed for these two assays (n=4). (Data represented as Mean ± SD).

Year:

2025

There remains an unmet clinical need for improved treatment strategies in Acute Myeloid Leukemia (AML). Although radiopharmaceutical therapies targeting non-cancer-selective antigens have shown promise in AML, their clinical utility is often limited by prolonged bone marrow suppression. Using a unique proteomics-based strategy, we recently identified the active conformation of integrin-β2 (aITGB2) as a novel, tumor-selective target for AML. Importantly, this conformational epitope is expressed widely on AML cells but minimally on normal marrow progenitors/healthy tissues. Here we first confirmed widespread aITGB2 expression on AML tumors that was largely independent of tumor genotype or prior therapeutic regimen. We developed diagnostic and therapeutic radiopharmaceuticals targeting aITGB2 utilizing a conformation-specific antibody (clone 7065). PET/CT imaging with 89Zr and 134Ce-labeled 7065 in AML models revealed high target-mediated uptake, greater than that compared to standard of care [18F]-FDG. PET/CT imaging with [89Zr]DFO*-7065 showed reduced binding to normal bone marrow and immune cells in humanized immune system mice compared to [89Zr]DFO*-anti-CD33. For therapy, we developed [225Ac]Macropa-PEG4-7065 using an optimized chelator-linker combination. Treatment with [225Ac]Macropa-PEG4-7065 in Nomo-1 and PDX AML disseminated models delayed tumor growth and improved overall survival compared to controls, including [225Ac]DOTA-anti-CD33, a clinical stage-radioimmunotherapy under evaluation in AML. Relapsed tumors demonstrated persistent aITGB2 expression, supporting continued development of fractionated dosing schemes, and proteomics analysis indicated activation of TCA cycle and carbon metabolism pathways, consistent with therapy-induced stress responses. These findings highlight [89Zr]DFO*-7065 and [225Ac]Macropa-7065 as a promising aITGB2-targeted theranostic pair with potential for imaging and treatment in future clinical translation.

Year:

2025

Supplementary Table S2: The %IA/g values for biodistribution study of [89Zr]DFO-YS5 in PC3-Luc disseminated tumors, conducted 4 days post-injection (p.i.), utilized mice with PC3-Luc tumors at 5 weeks post-cell inoculations. The large intestine tissue from Mouse 1 was not recorded due to a technical error in the instrument.

Year:

2025

Supplementary Table S8: The %IA/g values for biodistribution of [89Zr]DFO-YS5 in the mice from early treatment (week 1 post inoculations) treated with 4.2 and 9.2 kBq of [225Ac]Macropa-PEG4-YS5.

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Collaborators (23)

Nancy Y. Greenland

-

UNITED STATES
View details

John C Yoon

Associate Professor

University of California Davis School of Medicine

UNITED STATES
View details

Arun Wiita

Associate Professor

University of California, San Francisco

UNITED STATES
View details

Aaron C. Logan

Professor

University of California

UNITED STATES
View details

Li Zhang

Professor

UCSF

UNITED STATES
View details

Emily Chan

Stanford University

UNITED STATES
View details

Henry VanBrocklin

Professor/ Director of Radiopharmaceutical Research

University of California, San Francisco

UNITED STATES
View details

Jiang He

Professor

University of Virginia

UNITED STATES
View details

David M. Wilson

University of California

UNITED STATES
View details

Renuka Sriram

University of California

UNITED STATES
View details

Emily Egusa

University of California, San Francisco

UNITED STATES
View details

Anil Parsram Bidkar

Assistant Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Myriam Chaumeil

Assistant Professor

UCSF

UNITED STATES
View details

Jonathan Chou

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

sinan wang

Assistant Professor

University of California, San Francisco

UNITED STATES
View details

Changhua Mu

Assistant Professional Researcher

University of California, San Francisco

UNITED STATES
View details

Robert R. Flavell

University of California

UNITED STATES
View details

Javier Caravaca Rodriguez

Staff Scientist/PI

Lawrence Berkeley National Laboratory

UNITED STATES
View details

Rahul Aggarwal

University of California

UNITED STATES
View details

Megha Basak

University of California, San Francisco

UNITED STATES
View details

Scott C. Kogan

University of California, San Francisco

UNITED STATES
View details

Corynn Kasap

University of California, San Francisco

UNITED STATES
View details

kondapa Naidu Bobba

Assistant professor

University of Tennessee

UNITED STATES
View details